Vascular endothelial‐cadherin as a marker of endothelial injury in preclinical Alzheimer disease-Reference-Cited by-同舟云学术

Vascular endothelial‐cadherin as a marker of endothelial injury in preclinical Alzheimer disease

Published:2022-11-07 Issue:12 Volume:9 Page:1926-1940
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann Clin Transl Neurol

Author:

Tarawneh Rawan¹²^ORCID,Kasper Rachel S.¹,Sanford Jessie³⁴,Phuah Chia‐Ling⁴⁵,Hassenstab Jason⁶,Cruchaga Carlos³⁴

Affiliation:

1. Department of Neurology University of New Mexico Albuquerque New Mexico USA

2. Center for Memory and Aging University of New Mexico Albuquerque New Mexico USA

3. Department of Psychiatry Washington University in St Louis St. Louis Missouri USA

4. NeuroGenomics and Informatics Center Washington University in St Louis Missouri USA

5. Department of Neurology Washington University in St Louis St. Louis Missouri USA

6. Department of Psychology Washington University in St Louis St. Louis Missouri USA

Funder

National Institutes of Health

Chan Zuckerberg Initiative

Hope Center for Neurological Disorders

Washington University School of Medicine

Publisher

Wiley

Subject

Neurology (clinical),General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acn3.51685

Reference87 articles.

1. The Clinical Problem of Symptomatic Alzheimer Disease and Mild Cognitive Impairment

2. Tangles and plaques in nondemented aging and ?preclinical? Alzheimer's disease

3. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

4. Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015

5. Reasons for failed trials of disease‐modifying treatments for Alzheimer disease and their contribution in recent research;Yiannopoulou KG;Biomedicine,2019

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spontaneous cerebrovascular reactivity at rest in older adults with and without mild cognitive impairment and memory deficits;2024-06-19

2. Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review;Alzheimer's Research & Therapy;2024-04-27

3. Advances in nanoprobes for molecular MRI of Alzheimer's disease;WIREs Nanomedicine and Nanobiotechnology;2024-03

4. Fluid biomarkers of the neurovascular unit in cerebrovascular disease and vascular cognitive disorders: A systematic review and meta-analysis;Cerebral Circulation - Cognition and Behavior;2024

5. Neuropathology-based GWAS for Alzheimer’s disease reveals novel susceptibility loci and highlights sex-specific pathways;2023-12-18